Log In
Print this Print this

T-VEC, talimogene laherparepvec (formerly OncoVEX GM-CSF)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionModified herpes simplex virus type 1 (HSV-1) carrying the gene for GM-CSF
Molecular Target
Mechanism of ActionOncolytic virus
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentRegistration
Standard IndicationMelanoma
Indication DetailsTreat melanoma; Treat metastatic melanoma
Regulatory Designation U.S. - Special Protocol Assessment (Treat metastatic melanoma);
U.S. - Standard Review (Treat metastatic melanoma);
EU - Standard Review (Treat metastatic melanoma)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today